antibody-dependent cell cytotoxicity
Expansion of allogeneic NK cells with efficient antibody-dependent cell cytotoxicity against multiple tumors
... NK cell dysfunction [7, ...NK cell differentiation may be inhibited by the presence of tumor cells, ...NK cell-mediated therapy after hematopoietic stem cell transplantation (HSCT) seems safe ...
14
Antibody-Dependent Cell-Mediated Cytotoxicity in Simian Immunodeficiency Virus-Infected Rhesus Monkeys
... the antibody-dependent cell-mediated cytotoxicity (ADCC) response during acute and chronic SIVmac251 infection of rhesus ...NK cell expression of CD107a with NK cell expression ...
7
Monoclonal antibodies targeting cancer: 'magic bullets' or just the trigger?
... The first monoclonal antibodies (mAbs) approved for cancer therapy are now in Phase II and III trials, but the critical mechanism(s) determining efficacy and response in patients are still largely undefined. Both the ...
5
Antibody dependent cell mediated cytotoxicity in selected autoimmune diseases
... Antibody-dependent cell-mediated cytotoxicity mediated by peripheral blood lymphocytes was studied in patients with systemic lupus erythematosus, polyarteritis ...erythrocyte antibody. ...
8
Human Monocyte Antibody Dependent Cell Mediated Cytotoxicity to Tumor Cells
... lyse antibody-coated targets but not nonantibody- coated target ...using antibody-coated target cells that were selectively lysed by lymphocytes but not ...tumor cell targets may prove to be a useful ...
10
Antibody Dependent Cellular Cytotoxicity Competent Antibodies against HIV 1 Infected Cells in Plasma from HIV Infected Subjects
... We envision that the ADCC-AnV assay described here using sorted infected CEM cells as target cells may be useful for immune monitoring of HIV vaccine trials and therapeutic approaches that aim to induce anti-Env-specific ...
21
Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment
... The importance of utilizing mAb therapy to elicit ADCC- mediated tumor clearance was initially established by studies exploring the mechanism of action of rituximab. One of the primary mechanisms by which rituximab ...
10
Anti tumor activity and toxicokinetics analysis of MGAH22, an anti HER2 monoclonal antibody with enhanced Fcγ receptor binding properties
... overexpressed cell-surface oncoprotein that contributes to breast, gastric, and other cancers [1], is a validated therapeutic target, as evidenced by clinical suc- cess of the monoclonal antibody (mAb) ...
14
Antigenic specificity of antibody-dependent cell-mediated cytotoxicity directed against human immunodeficiency virus in antibody-positive sera.
... Downloaded from http://jvi.asm.org/ on November 10, 2019 by guest a Expression of HIV proteins in RH-LCL cells 16 h after infection with recombinant VV vectors, determined by radioimmuno[r] ...
7
Investigating remission and relapse in type 1 diabetes. Immune correlates of clinical outcome in beta-cell replacement therapies
... complement-dependent cytotoxicity test against ...expressing cell lines [322] and on single antigen beads ...HLA antibody staining was assessed by comparing fluorescence on insulin positive ...
90
Recent advances of bispecific antibodies in solid tumors
... bispecific antibody BiSS (Bispecific antibody with Single domain, Single domain antibodies) was constructed by tandemly linking two single domain antibodies, anti-CEA, and ...and cytotoxicity to ...
16
A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies
... B cell lines and primary malignant B cells from patients in the presence or in absence of purified NK cells isolated from healthy ...the antibody dependent cellular cytotoxicity (ADCC) ...
13
Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity
... NK cell effector functions [42] impair- ing TGF-β pathway which, among other effects, induces downregulation of the activating NK cell receptor NKG2D ...anti-PD-1 antibody (pidilizumab, CT-011) ...
12
Incomplete Downregulation of CD4 Expression Affects HIV-1 Env Conformation and Antibody-Dependent Cellular Cytotoxicity Responses
... by antibody-dependent cellular cyto- toxicity (ADCC) mediated by CD4-induced (CD4i) antibodies and sera from HIV-1-infected individuals (HIV ⫹ ...the cell surface resulted in the exposure of ...
16
A novel autoantibody against fibronectin leucine rich transmembrane protein 2 expressed on the endothelial cell surface identified by retroviral vector system in systemic lupus erythematosus
... ADCC: antibody-dependent cell-mediated cytotoxicity; AECAs: anti- endothelial cell antibodies; APC: allophycocyanin; AUs: arbitrary units; CDC: complement-dependent ...
13
Lysis of dengue virus-infected cells by natural cell-mediated cytotoxicity and antibody-dependent cell-mediated cytotoxicity.
... PBMC lysed Raji cells persistently infected with dengue 4 virus to a higher level than uninfected Raji cells, and the addition of anti-dengue 4 antibody further increased the lysis of PB[r] ...
8
Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions
... T cell precursor acute lymphoblastic leukemia (ETP-ALL), a high-risk subset of T-ALL, highly express CD7 ...the cell surface fol- lowing ligation of the antigen with an anti-CD7 ...the cell surface ...
21
Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders
... regulate cell growth and survival [87]. Engagement of the TCR by either antibody cross-linking or major histocompatibility complex pro- teins expressed by autologous lymphoma-associated macrophages ...
10
Multiple sclerosis: Immunopathology and treatment update
... MAIT cells are a subset of T cells of the innate immune system to defend against microbial infections. They are present in the liver, lungs, mucosa and blood and make up to 25% of CD8 T cells in healthy individuals; they ...
27
Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases
... antigen-presenting cell. Ibalizumab, a humanized mAb, binds CD4 on T cell surface away from the binding site for MHC class II ...CD4+ cell coating by ibalizumab, which was maintained longer in the ...
17